The increasing survival of children with cancer has been one of the greatest success stories in the practice of medicine during the past half century. Childhood cancer mortality has decreased by .50% from 1975 to 2006. 1, 2 Much of this substantial improvement in survival is directly attributable to increasing enrollment of children with cancer in clinical trials. [2] [3] [4] [5] Clinical trials allow more effective therapeutic treatments to be identified and provided to patients with cancer. For many decades, national clinical trials designed for children were primarily focused on children ,15 years of age. 6 Indeed, the first national clinical trials in the United States were conducted in the mid-1950s in young children with acute lymphoblastic leukemia and Wilms tumor who were predominantly ,5 years of age. The focus on younger children has resulted in a lack of clinical trials for older adolescents aged 15 to 19 years of age. The proportion of patients with cancer enrolled in a National Cancer Institute (NCI)-sponsored treatment trial has been shown to decrease with age (Fig 1) . 7 Although the majority of children under the age of 15 years are enrolled in clinical trials, ,20% of adolescents aged 15 to 19 years are enrolled in clinical trials. [3] [4] [5] [7] [8] [9] [10] This situation has led to gaps in survival rates between adolescents and younger children for many types of cancer (Fig 2) . Across most pediatrictype cancers, children .15 years of age have had less progress in survival prolongation compared with children ,15 years of age. [11] [12] [13] [14] Figure 3 The lack of clinical trial enrollment among adolescents with cancer undoubtedly has played a central role in the lack of improved survival in this population. One reason adolescents with cancer are not enrolled in clinical trials is the treatment setting in which they receive care. Adolescents suspected of cancer are referred by primary care physicians to either pediatric or adult oncologists. However, there is increasing evidence that adolescents treated by pediatric oncologists and at NCI-sponsored cancer centers are more likely to be enrolled in a clinical trial. Despite this finding, more adolescents are treated by adult oncologists and referrals to adult oncologists increase with the increasing age of adolescents. [15] [16] [17] [18] This is shown in Fig 4: with every year of age above 14, the proportion of newly diagnosed patients with cancer referred to the only children' s hospital in the region declined an average of 14% per year, from 85% Clinical trials accrual data were provided by the Cancer Therapy Evaluation Program, NCI. Population data were obtained from the US Census Bureau. 7 
FIGURE 2
Gap in survival rates for selected cancers in 15-to 19-year-olds versus those in ,15-year-olds. 14 in 14 year-olds to ,5% in 21-year-olds. A small proportion of the age group was referred to the comprehensive cancer center at the region' s academic medical center. The majority remained in private practice, with approximately one-third of these at practices not certified by the American College of Surgeons. Because the treatment setting in which adolescents are referred to receive their cancer workup and treatment is so critical, pediatricians play a key role in shaping the long-term outcomes of adolescents with cancer.
The Carolyn Price Walker Act of 2008 authorized federal agencies to expand and enhance research, surveillance, and awareness activities related to pediatric cancer, including improving access to clinical trials for children with cancer. 19 To ensure that adolescents shared in the improvements in cancer survival seen among younger children, the CDC initiated a project to identify the salient issues and measures to address this problem. We first performed a literature review of the available evidence on this topic. Next, we convened an informal workgroup of leading pediatric and adult oncologists, behavioral scientists, nurses, and researchers from academia and government (Table 1) . We then held a series of 3 webinars with the workgroup to define barriers to clinical trial enrollment and to provide recommendations on addressing them. This monograph, which includes a series of articles, is intended to raise awareness among pediatricians, the predominant type of primary care physician caring for adolescents, about the unique challenges of clinical trial enrollment among adolescents with cancer. 
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FIGURE 4
Referral patterns of patients with newly diagnosed cancer before age 25, by age, to the state children' s hospital and the state university adult center. Modified from reference 16. to design clinical trials when survival rates are already high in some diseases, but continued efforts are needed in incorporating AYA-specific aims into cooperative group trials. Although collaboration between pediatric and adult oncology cooperative groups is ideal, the complexities of regulatory barriers may overshadow the pursuit of such partnerships as shown by Judy Felgenhauer, Vice-Chair of the Children' s Oncology Group AYA Steering Committee. 27 The psychosocial barriers to clinical trial enrollment and adherence are further discussed by Natasha Buchanan in this monograph.
A major clinical trial enrollment barrier identified through the webinars was the decreased number of referrals of AYAs with cancer to an NCI-sponsored institution. Adolescents are often treated at community hospitals and private oncology practices. 16, 17 The drop-off in referral rates to a children' s hospital among adolescents over the age of 15 years of age is dramatic and helps explain the decline in enrollment in NCIsponsored trials. Across most pediatric types of cancers, children .15 years of age generally have lower overall survival rates compared with children In 2012, the National Comprehensive Cancer Network (NCCN) published the first-ever AYA clinical practice guidelines. 28 The NCCN is a not-for-profit alliance of 21 leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer. The establishment of the NCCN AYA guidelines is instrumental in increasing the awareness among oncologists about AYA cancers and may have an impact on referral patterns of AYA patients.
The barriers identified through this series of webinars are straightforward yet challenging. Successfully addressing these challenges will require improving referral to existing clinical trials, addressing regulatory barriers to clinical trial enrollment, increasing the number of clinical trials for adolescents, and addressing the unique psychosocial barriers to clinical trial enrollment and adherence for adolescents with cancer. Primary care physicians, and in particular pediatricians, play a key role in addressing these challenges. Closer engagement between pediatricians and the pediatric and adult oncology communities is needed to ensure that adolescents with cancer are referred to physicians and treatment centers that provide access to clinical trials. Collaboration between pediatricians and oncologists is also needed for the long-term well-being of adolescents with cancer.
